Search Results
You are looking at 1-2 of 2
Anthony Rengel,
Vienna Tran, and
Li Shean Toh
Article Category: Research Article
Volume/Issue: Volume 94: Issue 5
Online Publication Date: May 01, 2023
Page Range: 389 – 395
-effects.
25
Numerous advancements in osteoporosis pharmacotherapy have occurred in the last decade, including the introduction of the monoclonal antibody denosumab. Acting as an inhibitor of the receptor activator of nuclear factor kappa-Β (RANK) ligand (RANKL), denosumab selectively inhibits osteoclast activity via the RANKL-Osteoprotegerin (OPG) axis without impeding osteoblast activity to maintain bone density.
1
Unlike other antiresorptive therapies, it is available in a convenient 60-mg subcutaneous injection delivered every 6 mo.
1
,
27